IDIOPATHIC INFLAMMATORY MYOPATHIES

This early-phase study tests a new mRNA drug called MTS109 in 15 people with moderate to severe autoimmune diseases like lupus and scleroderma. The main goal is to check safety and side effects, not to cure the disease. Participants receive the drug by IV and are monitored closel…

This early-stage trial tests a new treatment called AZD0120, which uses a patient's own immune cells modified to target and calm overactive immune responses. It is for adults with systemic sclerosis, inflammatory myopathies, or difficult-to-treat rheumatoid arthritis. The main go…

This study tests a new treatment called NKX019, made from immune cells (natural killer cells) that are engineered to target and destroy certain immune cells causing disease. It is for people with autoimmune conditions like systemic sclerosis, inflammatory myopathies, or vasculiti…

This early-phase study tests whether a combination of two drugs, pozelimab and cemdisiran, can help people with sporadic inclusion body myositis (sIBM), a rare muscle disease that causes progressive weakness. Ten adults aged 45 to 75 with sIBM will receive the therapy and be moni…

This early-stage study tests a new treatment using a patient's own immune cells, modified to target and destroy faulty immune cells causing autoimmune diseases like lupus and scleroderma. The goal is to see if this 'reset' is safe and can control disease activity. About 20 adults…

This early-stage study tests a new drug called XmAb657 in 60 people, including healthy volunteers and those with autoimmune diseases like scleroderma or Sjögren's. The main goal is to check if the drug is safe and tolerable when given as an injection under the skin. Researchers w…

This early-stage study tests whether a new drug called AZD5492 is safe and tolerable in 72 adults with lupus, myositis, or rheumatoid arthritis. Participants receive either one or two doses under the skin and are monitored for side effects and drug levels over 6 months. The goal …

This study tests a drug that blocks a key immune signal (JAK1) in people with Behçet's disease, myositis, or IgG4-related disease. The goal is to see if it can control disease activity and reduce the need for long-term steroids. About 60 adults will take the drug and be monitored…

This study tests a new treatment called rapcabtagene autoleucel for people with severe idiopathic inflammatory myopathies (IIM) that haven't improved with standard therapies. IIM causes muscle weakness and inflammation. The treatment uses a patient's own immune cells that are mod…